Skip Navigation LinksHome > Academic & Industry > Data Sharing  
 

Data Sharing


If you are interested in utilizing ADCS trial data, please review the ADCS Data Access Policy and ADCS–Publication/Manuscript Citations Policy. Access to ADCS trial data remains restricted until the study's primary manuscript has been published. For the first year following publication, the study's data is available only to members of the ADCS Steeering Committee. After that time, any investigator may request the data. To request the data, complete the ADCS Data Access Request Form and submit to ADCSdataaccess@ucsd.edu.

For more information on access to ongoing studies, visit the Study Resources Page

NOTES:
* "OPEN" status projects are initially available for steering committee members and becomes available to the public 1 year following the     publication date.
** Link to primary publication will be added once it is made available.

Protocol NumberProtocol NameStudy DurationTreatmentDiagnostic Group(s)Instruments/BiomarkersActual BaselinedPrimary Paper Publication DateData Portal Status
ADC-001 Selegiline(SL) 24 monthsSelegiline or a-Tocopherol or Selegiline Placebo and a-tocopherol or selegiline and a-tocopherol placebo or PlaceboADADASCog, Blessed DRS, Blindness Eval, CDR, CERAD, ADL & Dependency Scale, Hackinski, MMSE, Modified UPDRSBL=341 04/1997   (Link to PubMed) Closed
ADC-002 New Instruments Trial(IN) 12 monthsNon-Drug StudyAD, NLADL, CDR, CERAD, CGIC, CMAI, Hachinski, Executive Function, Facial Recognition, Letter Cancellation, Functional Assessment Staging, GDS, MMSE, Praxis, Severe Impairment Battery, Verbal Memory Immediate & Delayed RecallBL=306 06/1997   (Link to PubMed) Closed
ADC-002 New Instruments Trial (Spanish)(IN) 12 monthsNon-Drug StudyAD, NLADL, CDR, CERAD, CGIC, CMAI, Hachinski, Executive Function, Facial Recognition, Letter Cancellation, Functional Assessment Staging, GDS, MMSE, Praxis, Severe Impairment Battery, Verbal Memory Immediate & Delayed RecallBL=94 06/1997   (Link to PubMed) Closed
ADC-003 Agitation(AP) 24 monthsHaloperidol or Trazodone or Behavior Techniques or PlaceboADAPOE, Abnormal Involuntary Movement Scale, Blindness Eval, CGIC, CMAI, CERAD, CMAI, Hackinski, MMSE, Lawton and Brody ADLBL=149 11/2000   (Link to PubMed) Closed
ADC-004 Prednisone(PR) 68 weeksPrednisone or PlaceboADADASCOG, ADASRECALL, ADAS RECOGNITION, APOE, Blessed Dimentia Rating, BPRS, Blindness Eval, CDR, Dependency Scale, HDRS, Hachinski, Lumbar, MMSE, UPDRSBL=138 02/2000   (Link to PubMed) Closed
ADC-005 Estrogen(ES) 12 months, plus 3 Months wash-outEstrogen(Premarin) or PlaceboADADASCog, ADASRECALL, ADAS RECOGNITION, APOE, Blindness Eval, BDRS, CDR, CSF, CGIC, Dependence Scale, Emotional Recognition, Hachinski, Hamilton, Lumbar Puncture, MAACL, MMSE, Newdot, QOL, Trailpeg, UPDRSBL=120 02/2000   (Link to PubMed) Closed
ADC-007 Melatonin(ML) 8 weeks, plus 2 Weeks placebo washoutMelatonin or PlaceboADADASCog, ADAS RECOGNITION, ADASRL, ADL, APOE, Blindness Eval, COSTINF, EMOTION, Hamilton, Hachinski, MMSE, NPI, Parasomnia Questionnaire, QOL, Sleep Disorder Inv, UPDRSBL=157 11/2003   (Link to PubMed) Closed
ADC-008 Mild Cognitive Impairment(MCI) 36 months, plus 4 months donepezil visitsVitamin E or Donepezil HCL (Aricept) or PlaceboMCIADACog, ADL, APOE/DNA Storage, Beck, Blindness Eval,MCI-CGIC, CDR, CT/MRI, GDS, Hamilton, Hachinski, Logical Memory I and II, MMSE, Neuropsychological Battery, Oxidative Biomarkers/DNA Storage, QOL, RUIBL=769 06/2005   (Link to PubMed) Closed
ADC-010 Normal Control(NL) 36 months Non-Drug StudyNLADACog, ADL, APOE/DNA Storage, Beck, Blindness Eval, Cleveland QOL, CGIC, CDR, GDS, Hamilton, Hachinski, Logical Memory I and II, MMSE, Neuropsychological Battery, QOL, RUITarget Enrollment=100 Pending   Closed
ADC-011 NSAIDS / Non-Steroidal(NS) 12 months plus 2 months wash-outVioxx (Rofecoxib)25 mg or Alleve (Naproxen) 200 mg or PlaceboADADASCog, ADL, APOE/DNA, Blindness Eval, CDR, CT/MRI, Hachinski, MMSE, NPI, QOL, RUI351 06/2003   (Link to PubMed) Closed
ADC-012 Valproate(VP) 6 weeks, plus 6 weeks open labelDivalproex Sodium or PlaceboADBPRS, CMAI, Hachinski, MMSEBL=153 11/2005   (Link to PubMed) Closed
ADC-013 Prevention Instruments(PI) 48 MonthsNon-Drug StudyMCI, NLADL, APOE/DNA Storage, Behavioral Scale, Boston Naming, CDR, CGIC-IRPV, CGIC-SAPV, Cognitive Scale, Efficiency, Free and Cued Selective Reminding, GDS, Cognitive Function Screening Instruments, QOL, MMSE, NPI, NYU Paragraph, RUI, Trails A & B and WAIS-RBL=662 Pending   Closed
ADC-013 Prevention Instruments - Web Based(PIWEB) 48 MonthsNon-Drug StudyMCI, NLADL, APOE/DNA Storage, Behavioral Scale, Boston Naming, CDR, CGIC-IRPV, CGIC-SAPV, Cognitive Scale, Efficiency, Free and Cued Selective Reminding, GDS, Cognitive Function Screening Instruments, QOL, MMSE, NPI, NYU Paragraph, RUI, Trails A & B and WAIS-RBL=55 Pending   Closed
ADC-014 TAP/DAP or Diffuse Lewy Body(TA) 10 weeksQuetiapine(Seroquel) or Donepezil (Aricept) or Quetiapine(Seroquel) and Donepezil (Aricept) or PlaceboAD, DLBADL, BPRS, CGIC, MMSE, NPI, R-MDS-D, UPDRSBL=40 04/2007   (Link to PubMed) Closed
ADC-015 Simvastatin (LL) 18 monthsSimvastatin or PlaceboADADASCog, APOE/DNA Storage, Blindness Eval ,CGIC, Dependency Scale, Hachinski, MMSE, NPI, QOL, RUITarget enrollment=406 08/2011   (Link to PubMed) Closed
ADC-016 Homocysteine(HC) 18 monthsFolate, Vitamin B6, Vitamin B12 or PlaceboADADASCog, ADL, APOE/DNA Storage, Blindness Eval, CDR, CT/MRI, Hachinski, QOL, MMSE, NPI, RUIBL=409 10/2008   (Link to PubMed) Closed
ADC-022 Valproate Neuroprotection(VN) 24 months. Plus 2 months wash-outValproate or PlaceboADADL, ADASCog, APOE, CDR, CGIC, Biomarker, ClinEval, CDR, CMAI, CT/MRI, Family History, MMSE, NPI, QOLTarget enrollment=300 08/2011   (Link to PubMed) Closed
ADC-023 Huperzine(HU) 24 weeks,plus Open Label Phase I up to 48 weeks, and Open Label Phase II up to 72 weeks.Huperzine A or PlaceboADADASCog, ADL, Blindness Eval, CGIC, CT/MRI, Hachinski, MMSE, NPIBL=210 04/2011   (Link to PubMed) Closed
ADC-025 Antioxidant(AX) 16 weeks plus followup phone callVitamin E plus Vitamin C plus a-Lipoic Acid and Coenzyme Q, or PlaceboADADL, Biomarkes, BPRS, GDS, Hachinski, Lumbar Puncture, MMSETarget enrollment=75 07/2012   (Link to PubMed) Closed
ADC-027 Docosahexaenoic Acid(DHA) 18 monthsDocosahexaenoic Acid or PlaceboADADAS-Cog, ADCS-ADL, APOE, CDR-SOB, FFQ, Hachinski, Lumbar puncture, MMSE, MRI, NPI, QOLBL=402 11/2010   (Link to PubMed) Closed